| 2024-02-02 | +31.9% | news | Seeking Alpha | Tyra Biosciences spikes on $200M private financing |
| 2024-10-25 | -30.8% | news | Seeking Alpha | Tyra stock plunges 17% amid TYRA-300 study data release |
| 2024-10-25 | -30.8% | legal | SEC EDGAR | TYRA 8-K: 5.02, 7.01, 8.01 (SEC Filing) |
| 2021-11-03 | +28.7% | legal | SEC EDGAR | TYRA 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-10-28 | -23.4% | legal | SEC EDGAR | TYRA 8-K: 8.01 (SEC Filing) |
| 2024-02-01 | +23.1% | legal | Seeking Alpha | Tyra gets FDA Rare Pediatric Disease status for dwarfism drug |
| 2024-02-01 | +23.1% | legal | SEC EDGAR | TYRA 8-K: 8.01 (SEC Filing) |
| 2023-04-21 | -17.7% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Tyra Biosciences (TYRA) - Zacks Investment Research |
| 2022-10-03 | -17.7% | legal | SEC EDGAR | TYRA 8-K: 1.01 and (SEC Filing) |
| 2022-08-04 | +11.4% | earnings | Seeking Alpha | Tyra Biosciences GAAP EPS of -$0.36 |
| 2022-08-04 | +11.4% | legal | SEC EDGAR | TYRA 8-K: 2.02 and (SEC Filing) |
| 2022-03-03 | -10.2% | legal | SEC EDGAR | TYRA 8-K: 2.02 and (SEC Filing) |
| 2025-05-08 | +9.9% | earnings | Seeking Alpha | Tyra Biosciences GAAP EPS of -$0.47 |
| 2025-05-08 | +9.9% | legal | Seeking Alpha | Tyra Biosciences files $500M mixed securities shelf |
| 2025-05-08 | +9.9% | legal | SEC EDGAR | TYRA 8-K: 2.02 and (SEC Filing) |
| 2024-10-18 | +9.0% | news | Seeking Alpha | Tyra raised to buy by BofA ahead of TYRA-300 data readout |
| 2024-10-18 | +9.0% | legal | SEC EDGAR | TYRA 8-K: 3.02 and (SEC Filing) |
| 2024-10-18 | +9.0% | news | Seeking Alpha | Tyra raised to buy by BofA ahead of TYRA-300 data readout (NASDAQ:TYRA) - Seeking Alpha |
| 2025-04-14 | +8.1% | news | Intellectia AI | TYRA Forecast — Price Prediction for 2026. Should I Buy TYRA? - Intellectia AI |
| 2021-09-17 | -7.9% | legal | SEC EDGAR | TYRA 8-K: 5.03, 8.01 (SEC Filing) |
| 2021-09-17 | -7.9% | earnings | MarketBeat | Tyra Biosciences (TYRA) Stock Price, News & Analysis $TYRA - MarketBeat |
| 2023-03-01 | -7.9% | legal | SEC EDGAR | TYRA 8-K: 5.02 and 8.01 (SEC Filing) |
| 2026-02-23 | +7.6% | news | PR Newswire | Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium - PR Newswire |
| 2022-11-03 | -7.5% | earnings | Seeking Alpha | Tyra Biosciences GAAP EPS of -$0.30 beats by $0.11 |
| 2022-11-03 | -7.5% | legal | SEC EDGAR | TYRA 8-K: 2.02, 5.02 (SEC Filing) |
| 2026-04-07 | -7.2% | news | Stock Titan | FMR LLC holds 14.4% of Tyra Biosciences (NASDAQ: TYRA) - Stock Titan |
| 2024-11-07 | -7.1% | legal | SEC EDGAR | TYRA 8-K: 2.02 and (SEC Filing) |
| 2024-02-05 | +7.1% | legal | SEC EDGAR | TYRA 8-K: 1.01, 3.02, 7.01 (SEC Filing) |
| 2025-12-01 | -7.0% | legal | SEC EDGAR | TYRA 8-K: 5.02 (SEC Filing) |
| 2026-03-27 | -7.0% | news | Investing.com | Tyra Biosciences director Kaplan sells shares worth $528k - Investing.com |
| 2026-02-19 | +7.0% | news | Stock Titan | Biotech Tyra Biosciences lines up five investor events from Boston to Miami - Stock Titan |
| 2026-03-31 | +7.0% | earnings | MarketBeat | Tyra Biosciences (NASDAQ:TYRA) Trading 9.8% Higher - Should You Buy? - MarketBeat |
| 2023-11-07 | -6.6% | legal | SEC EDGAR | TYRA 8-K: 2.02 and (SEC Filing) |
| 2026-02-20 | +6.6% | news | DirectorsTalk Interviews | Tyra Biosciences, Inc. (TYRA) Stock Analysis: A Biotech With 57% Potential Upside - DirectorsTalk Interviews |
| 2025-06-30 | +6.4% | legal | SEC EDGAR | TYRA 8-K: 8.01 (SEC Filing) |
| 2024-11-08 | -5.9% | earnings | Seeking Alpha | Tyra Biosciences GAAP EPS of -$0.41 beats by $0.06 |
| 2023-12-22 | +5.9% | legal | SEC EDGAR | TYRA 8-K: 8.01 (SEC Filing) |
| 2022-11-29 | +5.5% | legal | SEC EDGAR | TYRA 8-K: 8.01 (SEC Filing) |
| 2024-03-19 | +5.5% | earnings | Seeking Alpha | Tyra Biosciences GAAP EPS of -$0.53 misses by $0.05 |
| 2024-03-19 | +5.5% | news | Seeking Alpha | Tyra Biosciences files to sell 15.37M shares of common stock for holders |
| 2024-03-19 | +5.5% | legal | SEC EDGAR | TYRA 8-K: 2.02 and (SEC Filing) |
| 2026-04-06 | -5.3% | earnings | MarketBeat | Canaccord Genuity Group Begins Coverage on Tyra Biosciences (NASDAQ:TYRA) - MarketBeat |
| 2026-04-06 | -5.3% | news | Xã Vĩnh Công | Is Tyra Biosciences (TYRA) Stock a Good Buy in 2026 | Price at $38.93, Down 1.72% - Expert Entry Points - Xã Vĩnh Công |
| 2022-09-13 | +5.1% | analyst | TradingView | TYRA Forecast — Price Target — Prediction for 2027 - TradingView |
| 2025-10-01 | -4.7% | news | simplywall.st | We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth - simplywall.st |
| 2025-01-29 | -4.5% | legal | SEC EDGAR | TYRA 8-K: 5.02 (SEC Filing) |
| 2026-03-04 | +4.5% | news | Simply Wall St. | Did Deeper Losses and Dabogratinib Progress Just Shift Tyra Biosciences' (TYRA) Investment Narrative? |
| 2026-03-04 | +4.5% | legal | SEC EDGAR | TYRA 8-K: 8.01 (SEC Filing) |
| 2026-03-04 | +4.5% | news | Investing.com | Tyra Biosciences announces $126 million stock sale in block transaction - Investing.com |
| 2026-03-04 | +4.5% | news | TipRanks | Tyra Bioscience Raises $126 Million in Block Share Sale - TipRanks |
| 2024-05-09 | -4.5% | legal | SEC EDGAR | TYRA 8-K: 2.02 and (SEC Filing) |
| 2023-05-04 | -4.5% | earnings | Seeking Alpha | Tyra Biosciences GAAP EPS of -$0.28 beats by $0.09 |
| 2023-05-04 | -4.5% | legal | SEC EDGAR | TYRA 8-K: 2.02 and (SEC Filing) |
| 2022-05-05 | +4.2% | legal | SEC EDGAR | TYRA 8-K: 2.02 and (SEC Filing) |
| 2025-11-05 | -4.1% | legal | SEC EDGAR | TYRA 8-K: 2.02 and (SEC Filing) |
| 2026-04-20 | +4.0% | news | Stock Titan | 44,400 Tyra Biosciences (TYRA) stock options granted to director Dable - Stock Titan |
| 2026-04-20 | +4.0% | news | Stock Titan | Tyra Biosciences (TYRA) director Dable Habib J files Form 3 showing no share ownership - Stock Titan |
| 2024-05-10 | +4.0% | earnings | Seeking Alpha | Tyra Biosciences GAAP EPS of -$0.35 beats by $0.11 |
| 2025-11-23 | +3.9% | news | simplywall.st | Insiders Who Sold US$628k Of Tyra Biosciences Made The Right Call - simplywall.st |
| 2026-03-20 | -3.7% | news | Motley Fool | This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position |
| 2023-11-08 | -3.6% | earnings | Seeking Alpha | Tyra Biosciences GAAP EPS of -$0.49 misses by $0.14 |
| 2024-07-23 | +3.4% | earnings | Seeking Alpha | Lots Of Bullish Signals, But No Revenue Or Earnings From Tyra Biosciences |
| 2024-01-31 | -3.4% | analyst | eToro | TYRA Stock Price | Analyst Target 49.17 & Consensus - eToro |
| 2024-10-21 | +3.3% | news | Seeking Alpha | Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point |
| 2026-04-17 | -3.1% | executive | PR Newswire | Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors |
| 2026-04-17 | -3.1% | legal | SEC EDGAR | TYRA 8-K: 5.02 (SEC Filing) |
| 2026-04-17 | -3.1% | executive | Quiver Quantitative | Tyra Biosciences, Inc. ($TYRA) CEO 2025 Pay Revealed - Quiver Quantitative |
| 2026-04-17 | -3.1% | news | DirectorsTalk Interviews | Tyra Biosciences, Inc. (TYRA) Stock Analysis: Unveiling a 45.89% Potential Upside in Biotech Innovation - DirectorsTalk Interviews |
| 2026-04-17 | -3.1% | executive | Stock Titan | Former Acceleron CEO Habib Dable joins Tyra board as Kaplan exits - Stock Titan |
| 2026-04-17 | -3.1% | news | Stock Titan | Habib Dable joins Tyra Biosciences (NASDAQ: TYRA) board as Class II director - Stock Titan |
| 2026-04-17 | -3.1% | news | Stock Titan | Tyra Biosciences (TYRA) details 2026 virtual meeting, director votes and auditor - Stock Titan |
| 2026-04-17 | -3.1% | analyst | Investing.com India | Cantor Fitzgerald reiterates Tyra Biosciences stock rating By Investing.com - Investing.com India |
| 2026-01-23 | -2.9% | analyst | Investing.com | Piper Sandler raises Tyra Biosciences stock price target to $42 on growth outlook - Investing.com |
| 2026-03-21 | -2.7% | news | simplywall.st | Boone Capital Backs Tyra Biosciences As FGFR3 Trials Shape Outlook - simplywall.st |
| 2022-05-13 | -2.6% | news | Seeking Alpha | Tyra Biosciences (TYRA) Investor Presentation - Slideshow |
| 2026-04-01 | +2.6% | news | Investing.com | Tyra Biosciences stock hits all-time high at 39.21 USD - Investing.com |
| 2026-04-01 | +2.6% | news | Cổng thông tin điện tử Tỉnh Sơn La | TYRA Pulls Back: Market Rotation Hits Communication - Cổng thông tin điện tử Tỉnh Sơn La |
| 2025-03-01 | -2.5% | news | Seeking Alpha | Tyra Biosciences: FGFR1/2 Driven AE Data Spooked The Market |
| 2025-11-06 | -2.4% | earnings | Seeking Alpha | Tyra Biosciences GAAP EPS of -$0.50 beats by $0.05 |
| 2026-03-13 | +2.4% | news | Investing.com | Tyra Biosciences stock hits all-time high at 36.69 USD - Investing.com |
| 2026-03-18 | +2.3% | news | Motley Fool | Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit |
| 2026-03-18 | +2.3% | news | Motley Fool | Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit |
| 2026-03-26 | +2.3% | news | Stock Titan | Insider plans sale of 53,172 TYRA shares via option exercise (TYRA) - Stock Titan |
| 2025-03-27 | -2.3% | earnings | Seeking Alpha | Tyra Biosciences GAAP EPS of -$0.43 |
| 2025-03-27 | -2.3% | legal | SEC EDGAR | TYRA 8-K: 2.02 and (SEC Filing) |
| 2025-03-27 | -2.3% | news | PR Newswire | Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights - PR Newswire |
| 2026-04-04 | -2.2% | news | Simply Wall St. | A Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial Progress |
| 2026-04-04 | -2.2% | news | Sahm | Why Tyra Biosciences (TYRA) Is Up 9.1% After $126 Million Block Sale And R&D Push - Sahm |
| 2026-04-13 | -2.2% | news | Stock Titan | TYRA (Nasdaq) Form 144: Director reports two 8,000-share transactions - Stock Titan |
| 2023-08-11 | +2.1% | earnings | Seeking Alpha | Tyra Biosciences GAAP EPS of -$0.31 |
| 2023-06-01 | -2.0% | news | Seeking Alpha | Tyra Biosciences: Early Stage Developer Of Novel FGFR3-Selective Molecules |
| 2023-08-29 | +2.0% | legal | Seeking Alpha | Tyra Biosciences: FDA ODD Designation Progresses TYRA-300 |
| 2024-05-07 | -1.9% | legal | SEC EDGAR | TYRA 8-K: 5.02 (SEC Filing) |
| 2023-03-22 | -1.8% | earnings | Seeking Alpha | Tyra Biosciences GAAP EPS of -$0.31 beats by $0.05 |
| 2023-03-22 | -1.8% | legal | SEC EDGAR | TYRA 8-K: 2.02 and (SEC Filing) |
| 2024-03-26 | -1.7% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2025-08-22 | +1.5% | legal | SEC EDGAR | TYRA 8-K: 8.01 (SEC Filing) |
| 2026-04-15 | -1.5% | analyst | Benzinga | This Tyra Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga |
| 2024-09-25 | -1.3% | executive | Investing.com UK | Tyra Biosciences CEO sells over $283k in company stock By Investing.com - Investing.com UK |
| 2025-12-04 | -1.2% | analyst | Investing.com | Goldman Sachs initiates coverage of Tyra Biosciences stock with Early-Stage Biotech rating - Investing.com |
| 2024-08-15 | -1.2% | news | Seeking Alpha | Tyra Biosciences a new overweight at Piper Sandler as 'next gen FGFR company' |
| 2026-04-02 | +1.1% | legal | SEC EDGAR | TYRA 8-K: 5.02 (SEC Filing) |
| 2026-04-02 | +1.1% | news | Stock Titan | Tyra Biosciences (TYRA) VP details multi-year stock option grants - Stock Titan |
| 2026-04-02 | +1.1% | news | Stock Titan | Tyra Biosciences (NASDAQ: TYRA) taps Julia Rueb as principal accounting officer - Stock Titan |
| 2026-04-02 | +1.1% | news | Stock Traders Daily | Precision Trading with Tyra Biosciences Inc. (TYRA) Risk Zones - Stock Traders Daily |
| 2026-04-02 | +1.1% | news | TipRanks | Tyra Bioscience Strengthens Financial Leadership with New Officer - TipRanks |
| 2023-08-10 | +0.9% | legal | SEC EDGAR | TYRA 8-K: 2.02 and (SEC Filing) |
| 2024-08-07 | -0.9% | legal | SEC EDGAR | TYRA 8-K: 2.02 and (SEC Filing) |
| 2023-04-05 | -0.8% | news | CoinCodex | Tyra Biosciences, Inc. (TYRA) Stock Forecast & Price Prediction 2026–2030 - CoinCodex |
| 2026-04-22 | -0.6% | earnings | Cổng thông tin điện tử tỉnh Lào Cai | Tyra Biosciences (TYRA) Stock: Entry Strategy Overview | Q4 2025: EPS Misses Estimates - Community Buy Signals - Cổng thông tin điện tử tỉnh Lào Cai |
| 2026-02-13 | -0.5% | legal | DirectorsTalk Interviews | Tyra Biosciences, Inc. (TYRA) Stock Analysis: Exploring A 55% Upside In The Biotech Sector - DirectorsTalk Interviews |
| 2026-03-19 | -0.4% | news | Motley Fool | Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. |
| 2026-04-16 | +0.2% | earnings | MarketBeat | Tyra Biosciences (NASDAQ:TYRA) Stock Rating Upgraded by Guggenheim - MarketBeat |
| 2024-08-08 | +0.2% | earnings | Seeking Alpha | Tyra Biosciences GAAP EPS of -$0.32 |
| 2024-12-17 | -0.2% | news | Seeking Alpha | The Take On Tyra Biosciences |
| 2024-12-17 | -0.2% | news | Seeking Alpha | The Take On Tyra Biosciences (NASDAQ:TYRA) - Seeking Alpha |
| 2023-08-01 | +0.2% | legal | Seeking Alpha | Tyra Biosciences gets FDA orphan drug designation for dwarfism therapy |
| 2026-03-02 | -0.1% | earnings | MT Newswires | Tyra Biosciences Q4 Loss Widens |
| 2026-03-02 | -0.1% | news | PR Newswire | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights |
| 2026-03-02 | -0.1% | earnings | Seeking Alpha | Tyra Biosciences GAAP EPS of -$0.57 misses by $0.04 |
| 2026-03-02 | -0.1% | legal | SEC EDGAR | TYRA 8-K: 2.02 and (SEC Filing) |
| 2026-03-02 | -0.1% | news | PR Newswire | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights - PR Newswire |
| 2026-04-11 | +0.0% | earnings | MarketBeat | JPMorgan Chase & Co. Trims Position in Tyra Biosciences, Inc. $TYRA - MarketBeat |
| 2025-08-14 | +0.0% | earnings | Seeking Alpha | Tyra Biosciences GAAP EPS of -$0.47 |
| 2025-08-14 | +0.0% | legal | SEC EDGAR | TYRA 8-K: 2.02 and (SEC Filing) |
| 2026-04-25 | — | analyst | HarianBasis.co | Guggenheim Securities Issues Buy Rating for Tyra Biosciences - HarianBasis.co |
| 2026-04-24 | — | news | Insider Monkey | Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib |
| 2026-04-24 | — | news | Stock Titan | Canaan reports 750,000 shares in Tyra Biosciences (NASDAQ: TYRA) - Stock Titan |
| 2026-04-24 | — | news | Insider Monkey | Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib - Insider Monkey |
| 2021-09-15 | — | executive | Stock Titan | Latest TYRA News - Tyra Biosciences Announces Appointment of H... - Stock Titan |